PBRM1 and cancer: While progress is being made with monotherapies, combination immune therapies with immune checkpoint inhibitors are also being studied for use with mSWI/SNF mutations, particularly with ARID2, polybromo 1 (PBRM1), ARID1A, and SMARC1B in cancer (Fig. 4; Mittal and Roberts 2020).